Each year at the International Association of Defense Counsel annual meeting, the award is bestowed on the author or authors of the best article published in Defense Counsel Journal during the preceding year.
"After fewer than six hours of deliberations . . . the jury in Middlesex County Superior Court handed down its 7-1 decision in the case of Beverly Meng shortly after 11 a.m. Meng's lawsuit was the second to go on trial in the New Jersey mass tort, and Novartis has won both."
The DynCorp ruling is a welcome and much needed rebuke to international activist efforts to demonize U.S. industry through unfounded legal actions arising from international operations.
"A Florida federal judge on Wednesday nixed punitive damages from a lawsuit alleging Novartis Pharmaceuticals Corp.'s Aredia and Zometa bone drugs caused a woman to develop osteonecrosis of the jaw, finding that New Jersey law limiting punitive damages in such cases applies."
The American Lawyer journal highlights DynCorp's success as counter to Chevron's legal troubles in Ecuador.
The New Jersey Supreme Court has declined to hear a challenge to judgments for Novartis Pharmaceuticals Corp. in the first bellwether trial in consolidated litigation over claims the drugmaker's bone cancer drugs Aredia and Zometa caused jaw deterioration.